Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

The average prediction of analysts places 'Revenues- Libtayo- ROW' at $127.95 million. The estimate indicates a change of +22.2% from the prior-year quarter.

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion, while the ...

Patients with pathologically confirmed solid tumors were treated with ICIs consisting of anti-PD-1/PD-L1 blockade (nivolumab [Opdivo], pembrolizumab [Keytruda], atezolizumab [Tecentriq], cemiplimab ...

At close: 25 April at 4:00:00 pm GMT-4 ...